Quest Partners LLC Takes $160,000 Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Quest Partners LLC purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the third quarter, Holdings Channel reports. The firm purchased 23,044 shares of the company’s stock, valued at approximately $160,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. CWA Asset Management Group LLC bought a new stake in shares of GoodRx in the 3rd quarter worth approximately $370,000. Raymond James & Associates boosted its holdings in shares of GoodRx by 212.6% during the third quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after acquiring an additional 267,951 shares during the period. nVerses Capital LLC bought a new position in shares of GoodRx during the third quarter worth about $33,000. Vontobel Holding Ltd. increased its holdings in shares of GoodRx by 78.4% in the 3rd quarter. Vontobel Holding Ltd. now owns 93,750 shares of the company’s stock worth $651,000 after acquiring an additional 41,196 shares during the period. Finally, Kesler Norman & Wride LLC acquired a new stake in shares of GoodRx in the 3rd quarter worth about $420,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.17% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on GDRX. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. UBS Group lowered their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Barclays reduced their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a report on Friday, August 9th. Finally, Citigroup cut their price objective on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.86.

GoodRx Stock Up 2.1 %

NASDAQ GDRX opened at $4.86 on Friday. The company has a market capitalization of $1.85 billion, a P/E ratio of -162.00, a PEG ratio of 3.56 and a beta of 1.39. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company’s 50 day simple moving average is $6.02 and its 200 day simple moving average is $7.26.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.